Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul D Nathan

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic MelanomaReinhard Dummer, Georgina V Long, Caroline Robert, et al.
The New England Journal of Medicine|June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic MelanomaCaroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238James Larkin, Michele Del Vecchio, Mario Mandalá, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic MelanomaReinhard Dummer, Georgina V Long, Caroline Robert, et al.
The New England Journal of Medicine|June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic MelanomaCaroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238James Larkin, Michele Del Vecchio, Mario Mandalá, et al.
Pageof 3